Fibroblast Growth Factor-23 and Incident Atrial Fibrillation | Zendy

Jehu Mathew | Zendy; Michael C. Sachs | Zendy; Ronit Katz | Zendy; Kristen K. Patton | Zendy; Susan R. Heckbert | Zendy; Andrew N. Hoofnagle | Zendy; Álvaro Alonso | Zendy; Michel Chonchol | Zendy; Rajat Deo | Zendy; Joachim H. Ix | Zendy; David S. Siscovick | Zendy; Bryan Kestenbaum | Zendy; Ian H. de Boer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fibroblast Growth Factor-23 and Incident Atrial Fibrillation

Author(s) -

Jehu Mathew,

Michael C. Sachs,

Ronit Katz,

Kristen K. Patton,

Susan R. Heckbert,

Andrew N. Hoofnagle,

Álvaro Alonso,

Michel Chonchol,

Rajat Deo,

Joachim H. Ix,

David S. Siscovick,

Bryan Kestenbaum,

Ian H. de Boer

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.005499

Subject(s) - medicine , atrial fibrillation , fibroblast growth factor 23 , endocrinology , left ventricular hypertrophy , fibroblast growth factor , kidney disease , risk factor , muscle hypertrophy , excretion , cardiology , receptor , blood pressure , parathyroid hormone , calcium

Fibroblast growth factor-23 (FGF-23) is a hormone that promotes urinary phosphate excretion and regulates vitamin D metabolism. Circulating FGF-23 concentrations increase markedly in chronic kidney disease and are associated with increased risk of clinical cardiovascular events. FGF-23 may promote atrial fibrillation (AF) by inducing left ventricular hypertrophy and diastolic and left atrial dysfunction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research